Loading
A phase 3 trial testing ESG401 in HR-positive / HER2-negative breast cancer, now recruiting.
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer is a phase 3 interventional study registered as NCT06383767, led by Qilu Pharmaceutical, and recruiting on the registry. Official title: A Open-label, Randomised, Multicenter Phase III Study of ESG401 Versus Investigator's Choice Chemotherapy in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Had Failed at Least One Line of Chemotherapy. Planned enrolment is 378 participants (estimated). The study started in 2024-07-11 and primary completion is expected in 2027-06-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/